Humacyte Regains Nasdaq Compliance, Resolving Minimum Bid Price Delisting Threat
HUMA has more than doubled off its 52-week low of $0.547.
Summary
Humacyte, Inc. announced it has regained compliance with Nasdaq's minimum $1.00 bid price requirement, effectively resolving the previously disclosed delisting threat.
Key Events · Corporate Governance and Compliance · HUMA
-
Nasdaq Compliance Regained
Humacyte received notification from Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Global Select Market.
-
Delisting Threat Resolved
The company's common stock maintained a closing bid price of $1.00 or more for the required consecutive business days, leading Nasdaq to consider the matter closed and removing the previous delisting notice issued on May 4, 2026.
Analysis · HUMA · Life Sciences
This filing is highly important as it resolves a critical delisting threat that Humacyte faced. The company had previously received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement. Regaining compliance removes a significant overhang and uncertainty for investors, ensuring the company's continued listing on The Nasdaq Global Select Market. This is a positive development, especially given the company's recent financial challenges and going concern warning.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUMA was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $299.7M. The 52-week trading range was $0.55 to $2.93. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.